Exchange lesions and pruritus with abrocitinib in atopic dermatitis

Atopic dermatitis: with abrocitinib in large pazienti without lesions and with minor itching resulting from biological propagation

The number of serious diseases associated with atopic dermatitis and moderate serious wasting with abrocitinib 100 mg does not correspond to the strict composition of skin clearance, almost complete/complete, and the disintegration of pruritus resulting from treatment with dupilumab or placebo.

I received the test results after the Phase III trial. JADE COMPARISON 2024 Congress Presentation European Academy of Dermatology and Venereology (EADV) states that pharmaceutical products can provide complete and reliable treatment in this patient population segment.

La atopic dermatitis This is a chronic inflammatory skin disease that manifests itself as a severe eczematous lesion and intense itching. And patients who appeared more severely ill did not respond to the therapeutic theme, possibly using systemic therapy, where dupilumab was administered via sotocutanea at a dose of 300 mg every 2, when abrocitinib, a selective initiator in China 1 (JAK1), was given orally at a pediatric dose 100 or 200 mg.

Nello Studio di Phase III JADE DARE, and step by step instructions abrocitinib 200mg combined with topical therapy can help with earlier inflammation, premature response, within 2 days and at best when applying dupilumab to very stringent endpoints, which will definitely lead to better recovery or 90/100% response at basal levels. Eczema area and severity index (EASI 90/100) che si è mantenuto fino alla Fine dello studio alla settimana 26.

In a post-hoc analysis, a large percentage of patients treated with abrocitinib 200 mg were deviated from the combined response on the EASI 90 and 0 to 1 (reduction or quasi-pruritus) on the Peak Pruritus Numerical Rating Scale. (PP-NRS) rispetto and dupilumab from 2 to 26.

Negley endpoint: more stringent abrocitinib 100 mg versus dupilumab and placebo
Following an analysis presented at the congress, the efficacy of abrocitinib at all 100 mg daily doses, rispetto and dupilumab at 300 mg at the designated time (600 mg dose) was assessed, possibly not meeting the stringent endpoints of placebo in the JADE COMPARE trial.

I analyzed and obtained relative data in 238, 242, and 131 patients studying abrocitinib 100 mg, dupilumab, and placebo. Twice as many participants increased the endpoint of the EASI 90 + PP-NRS 0/1 adjunctive treatment with abrocitinib 100 mg, rispetto, dupilumab, and placebo, and they continued to increase until the end point in studio 16 (20.2% vs. 15.5% and 5.4%).

The 16 stress sets resulted in the highest percentages of patients who changed response to the very stringent EASI 100 (complete health gravity solution) and point 0/1 (free or quasi-free injury). ) Nell’Investigator’s Global Assessment (IGA) complements treatment with abrocitinib 100 mg, rispetto, dupilumab, or placebo.

Response to EASI 100 is a deviation statistic of 12.7%, 5.2%, and 4.0% of patients randomly using abrocitinib 100 mg, dupilumab, and placebo, and an IGA point of 0 days 12.6%, 6.5 % and 4.8% soggetti.

In a separate analysis, statistical data and data on patients who failed to respond to dupilumab in JADE COMPARE were obtained sequentially in the JADE EXTEND studio and were randomized statistical data on abrocitinib 100 mg. Percentage of patients who are unable to change the endpoint in the EASI 90 + itching with dual irritation composition for the entire period in JADE COMPARE, and this change must be strictly stringent with treatment with abrocitinib 100 mg for 92 periods in JADE EXTEND

Finally, I answered the question about the relator. Stefan Weidinger University Hospital dello Schleswig-Holstein di Kiel, Germany:

• Treatment of patients with abrocitinib 100 mg may be modified as a result of a complex response to cutaneous clearance, almost complete/complete, and one condition without more rapid pruritus, and than treated with dupilumab or placebo.
• Treatment with abrocitinib 100 mg based on the percentage of patients who changed the endpoint of dupilumab or placebo combination causing severe basal pruritus
• The percentage of patients who previously failed to respond to EASI is 90% greater than the dupilumab pruritic condition that resulted in the same outcome as treatment with abrocitinib 100 mg.
• Treatment with abrocitinib 100 mg may result in a strong response, and part of the initiation of treatment will not result in severe atopic dermatitis.

Reference

Weidinger S, et al. Strong response to skin clearance and freedom from itching with abrocitinib 100 mg versus dupilumab in patients with moderate to severe atopic dermatitis: a JADE COMPARE post hoc analysis. Presented at the 33rd Annual Congress of the European Academy of Dermatology and Venereology (EADV); Amsterdam, Netherlands; September 25–28, 2024

Correlati